Treatment decisions and survival for people with small-cell lung cancer

British Journal of Cancer

Volumn 110, Issue 4, 2014, Pages 908-915

  Powell, H A ^a   Tata, L J ^a   Baldwin, D R ^b   Potter, V A ^b   Stanley, R A ^c   Khakwani, A ^a   Hubbard, R B ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

^c Health and Social Care Information Centre   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PATIENT COMPLIANCE; SMALL CELL LUNG CARCINOMA; SURVIVAL; TREATMENT OUTCOME;

EID: 84894328470     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2013.812     Document Type: Article

References (18)

1. Burgers JA, Arance A, Ashcroft L, Hodgetts J, Lomax L, Thatcher N (2002) Identical chemotherapy schedules given on and off trial protocol in small cell lung cancer response and survival results. Br J Cancer 87: 562-566.
2. Charlson ME, Pompei P, Ales KL, Mackenzie CR (1987) A new method of classifying prognostic co-morbidity in longitudinal-studies-development and validation. J Chronic Dis 40: 373-383.
3. Elliss-Brookes L, McPhail S, Ives A, Greenslade M, Shelton J, Hiom S, Richards M (2012) Routes to diagnosis for cancer-determining the patient journey using multiple routine data sets. Br J Cancer 107: 1220-1226.
4. Fukuoka M, Furuse K, Saijo N, Nishiwaki Y, Ikegami H, Tamura T, Shimoyama M, Suemasu K (1991) Randomized trial of cyclophosphamide, doxorubicin, and vincristine versus cisplatin and etoposide versus alternation of these regimens in small-cell lung cancer. J Natl Cancer Inst 83: 855-861.
5. Health and social care information centre (2013) National Lung Cancer Audit [Online] Available at: Http://www.hscic.gov.uk/lung (accessed 7th August 2013).
6. Khakwani A, Rich AL, Tata LJ, PowellHA, Stanley RA, BaldwinDR, Hubbard RB (2013) The pathological confirmation rate of lung cancer in England using the NLCA database. Lung Cancer 79: 125-131.
7. Mcphail S, Elliss-Brookes L, Shelton J, Ives A, Greenslade M, Vernon S, Morris EJA, Richards M (2013) Emergency presentation of cancer and short-Term mortality. Br J Cancer 109: 2027-2034.
8. National cancer intelligence network (Hosted by Public Health England (2011) SACT Systemic Anti-cancer Therapy-Chemotherapy dataset [Online]. Available at: Http://www.chemodataset.nhs.uk/home.
9. National institute for health and clinical excellence (2011) The diagnosis and treatment of lung cancer (update) NICE guideline. NHS Information Centre (2012) National Lung Cancer Audit 2012, Report for the Audit period 2011.
10. Powell HA, Tata LJ, Baldwin DR, Stanley RA, Hubbard RB (2013) P15 Identifying patients who receive chemotherapy for small-cell lung cancer using large datasets. Thorax 68: A81.
11. Rich AL, Tata LJ, Free CM, Stanley RA, Peake MD, Baldwin DR, Hubbard RB (2011a) Inequalities in outcomes for non-small cell lung cancer: The influence of clinical characteristics and features of the local lung cancer service. Thorax 66: 1078-1084.
12. Rich AL, Tata LJ, Stanley RA, Free CM, Peake MD, Baldwin DR, Hubbard RB (2011b) Lung cancer in England: Information from the National Lung Cancer Audit (LUCADA). Lung cancer 72: 16-22.
13. Roth BJ, Johnson DH, Einhorn LH, Schacter LP, Cherng NC, Cohen HJ, Crawford J, Randolph JA, Goodlow JL, Broun GO (1992) Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive smallcell lung cancer: A phase III trial of the Southeastern Cancer Study Group. J Clin Oncol 10: 282-291.
14. Singh S, Parulekar W, Murray N, Feld R, Evans WK, Tu D, Shepherd FA (2005) Influence of sex on toxicity and treatment outcome in small-cell lung cancer. J Clin Oncol 23: 850-856.
15. Sundstrøm S, Bremnes RM, Kaasa S, Aasebø U, Hatlevoll R, Dahle R, Boye N, Wang M, Vigander T, Vilsvik J, Skovlund E, Hannisdal E, Aamdal S. Group, F. T. N. L. C. S. (2002) Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: Results from a randomized phase III trial with 5 years'follow-up. J Clin Oncol 20: 4665-4672.
16. Takada M, Fukuoka M, Kawahara M, Sugiura T, Yokoyama A, Yokota S, Nishiwaki Y, Watanabe K, Noda K, Tamura T, Fukuda H, Saijo N, Group, F. T. M. O. T. J. C. O. (2002) Phase III study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited-stage small-cell lung cancer: Results of the Japan Clinical Oncology Group Study 9104. J Clin Oncol 20: 3054-3060.
17. Turrisi AT, Kim K, Blum R, Sause WT, Livingston RB, Komaki R, Wagner H, Aisner S, Johnson DH (1999) Twice-Daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med 340: 265-271.
18. Union for international cancer control (2009) TNM Classification of Malignant Tumours, 7th edn. Wiley-Blackwell: Oxford, UK.